<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among 262 inpatients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> who were referred for chemotherapy or immunosuppressive therapy between January, 1985, and December, 1989, nine (3.4%) patients, including two with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), three with <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo>, one with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, two with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and one with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, were found to be <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus (HBV) carriers before their chemotherapy began </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> six HBV carriers who received chemotherapy containing <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> showed mild-to-moderate elevations in serum transaminase levels after the chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Five showed a rise in titer of the <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B surface antigen, HBsAg </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, three HBV carriers not receiving <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> showed no change in serum transaminase after chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>One HBV carrier with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> suffered from severe icteric <z:hpo ids='HP_0012115'>hepatitis</z:hpo> after the withdrawal of multiagent chemotherapy containing <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The HBV-DNA polymerase rose markedly and was accompanied by a marked rise in titer of HBsAg </plain></SENT>
<SENT sid="6" pm="."><plain>The results warn us to keep in mind the possibility of <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> inducing an activation of HBV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, which may result in severe <z:hpo ids='HP_0012115'>hepatitis</z:hpo> in some HBV carriers </plain></SENT>
<SENT sid="7" pm="."><plain>Although further investigation is required, it is recommended that HBsAg-positive patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> should, if possible, be treated without <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> </plain></SENT>
</text></document>